Loading
Locally Advanced Solid Tumor / Pembrolizumab / TNG462 · Phase 1/2 Trial
ClinicalTrials.gov · September 8, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a first-in-human, Phase 1/2 open-label study of TNG462, a selective PRMT5 inhibitor, in patients with MTAP-deleted solid tumors. The registry record describes study design and planned enrollment only; no efficacy or safety results have been posted.
Phase 1/2, Interventional, Non Randomized, Sequential, Open label, Treatment purpose. Locally Advanced Solid Tumor; age from 18 Years. Intervention: Dose Escalation; Dose Expansion in NSCLC; Dose Expansion in Mesothelioma; Dose Expansion in Pancreatic Ductal Adenocarcinoma; Dose Expansion in Sarcoma; Dose Expansion in Solid Tumors; Dose Expansion in NSCLC in Combination with Pembrolizu…. n = 225. 26 sites: United States, France, Spain.
This is a first-in-human, Phase 1/2 open-label study of TNG462, a selective PRMT5 inhibitor, in patients with MTAP-deleted solid tumors. The registry record describes study design and planned enrollment only; no efficacy or safety results have been posted.
No safety, tolerability, or anti-neoplastic activity data are reported.
This trial is in early recruitment and has not yet reported safety, tolerability, or efficacy data. Clinicians should not base treatment decisions on this registry entry.
This is a first-in-human, Phase 1/2 open-label dose escalation and expansion study with no results yet posted; only design and planned enrollment are available.
As stated by the source record.
Quoted from the source exactly as published.
This trial is in early recruitment and has not yet reported safety, tolerability, or efficacy data. Clinicians should not base treatment decisions on this registry entry.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05732831). This is a study registration, not published results. Lead sponsor: Tango Therapeutics, Inc.. Recruitment status: RECRUITING. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 225 participants (ESTIMATED). Conditions: Locally Advanced Solid Tumor. Interventions: DRUG: TNG462; DRUG: Pembrolizumab. Primary outcome measures: Phase 1 Maximum Tolerated Dose , 28 days and 21 days; Phase 1 Dosing Schedule , 28 days; Phase 2 Anti-neoplastic Activity , 16 weeks and 18 weeks. Brief summary: This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.